MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Incyte Corp

Затворен

СекторЗдравеопазване

85.4 -1.83

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

84.88

Максимум

86.99

Ключови измерители

By Trading Economics

Приходи

247M

405M

Продажби

163M

1.2B

P/E

Средно за сектора

19.555

35.739

Марж на печалбата

33.319

Служители

2,617

EBITDA

324M

582M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

-1.67% downside

Дивиденти

By Dow Jones

Следващи печалби

28.10.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

2.8B

16B

Предишно отваряне

87.23

Предишно затваряне

85.4

Настроения в новините

By Acuity

29%

71%

96 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Incyte Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.10.2025 г., 16:58 ч. UTC

Печалби

BMW Trims 2025 View, Citing Weaker Performance in China

7.10.2025 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7.10.2025 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7.10.2025 г., 23:19 ч. UTC

Пазарно говорене

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7.10.2025 г., 22:50 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.10.2025 г., 22:50 ч. UTC

Пазарно говорене

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7.10.2025 г., 22:40 ч. UTC

Пазарно говорене

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7.10.2025 г., 21:56 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

7.10.2025 г., 21:56 ч. UTC

Пазарно говорене

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.10.2025 г., 20:44 ч. UTC

Горещи акции

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7.10.2025 г., 19:42 ч. UTC

Пазарно говорене

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7.10.2025 г., 19:23 ч. UTC

Придобивния, сливания и поглъщания

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7.10.2025 г., 19:07 ч. UTC

Пазарно говорене

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7.10.2025 г., 19:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

7.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7.10.2025 г., 16:15 ч. UTC

Пазарно говорене

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7.10.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

7.10.2025 г., 15:37 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.10.2025 г., 15:37 ч. UTC

Пазарно говорене

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7.10.2025 г., 15:33 ч. UTC

Пазарно говорене

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7.10.2025 г., 15:25 ч. UTC

Пазарно говорене

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7.10.2025 г., 15:15 ч. UTC

Пазарно говорене

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7.10.2025 г., 15:04 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

7.10.2025 г., 15:04 ч. UTC

Пазарно говорене

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7.10.2025 г., 14:56 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.10.2025 г., 14:56 ч. UTC

Пазарно говорене

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7.10.2025 г., 14:52 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Incyte Corp Прогноза

Ценова цел

By TipRanks

-1.67% надолу

12-месечна прогноза

Среден 85.71 USD  -1.67%

Висок 115 USD

Нисък 60 USD

Според 19 анализатори от Wall Street, предложили 12-месечна ценова цел за Incyte Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

19 ratings

8

Купи

10

Задържане

1

Продай

Техническа оценка

By Trading Central

59.52 / 62.66Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

96 / 371 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat